New ankle pain shot could cut opioid use after surgery
NCT ID NCT07212114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two numbing medicines given as nerve blocks before total ankle replacement surgery. One is EXPAREL, a long-acting form of bupivacaine, and the other is standard bupivacaine. Researchers want to see if EXPAREL provides better pain relief and reduces the need for opioid painkillers in the days after surgery. About 104 adults having ankle replacement will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EXPAREL (a long-acting form of the numbing medicine bupivacaine)
- What this could lead to
- If it works, this could give patients longer-lasting pain relief after ankle replacement surgery and reduce the need for opioid painkillers.
- What could go wrong
- This is a single-center trial with only 104 people, so results may not apply to everyone. The improvement over standard care may be small or not meaningful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTSURGICAL ANALGESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Orthopaedic Hospital Musculoskeletal Institute (MSK)
RECRUITINGAtlanta, Georgia, 30329, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.